Exelixis (NASDAQ:EXEL) Chief Executive Officer Mike Morrissey said the company will continue to balance internal investment, clinical development and share repurchases with a data-driven approach as it manages the later stages of CABO’s exclusivity and advances zanza through multiple studies. Speaking at a BofA investor event hosted by pharma and biotech analyst Jason Gerberry, Morrissey [...]
Science thelincolnianonline May 16, 2026